North America Immunodiagnostic Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product [Enzyme-Linked Immunosorbent Assays, Chemiluminescence Immunoassays (Vitamin D Assay, HIV Detection, HIV Ag/Ab Combo Assay, and Others), Radioimmunoassays, and Others], Clinical Indication [Infectious Diseases (COVID-19, Lyme, Zika, Infection Management, TORCH, Tuberculosis, Treponema, Measles & Mumps, EBV, and VZV), Hepatitis+HIV, Gastrointestinal, Metabolics , Endocrinology (Hypertension, GROWTH, Diabetes, Thyroid, and Reproductive Endocrinology), and Others], and End User (Hospitals, Clinics, Diagnostic Laboratories, Academic & Research Institutes, and Others)
The North America immunodiagnostics market is expected to reach US$ 15,040.40 million by 2028 from US$ 9,188.19 million in 2021; it is estimated to grow at a CAGR of 7.3% during 2022–2028.
Immunodiagnostics primarily uses antigen–antibody reactions as its primary means of detection. Antibodies specific to the desired antigen can be conjugated with a radiolabel, fluorescent label, or color-forming enzyme and are used as a probe to detect it. The speed, accuracy, and simplicity of such tests have promoted them as rapid techniques for the diagnosis of diseases and the detection of illegal drugs. The growth of the North America immunodiagnostics market is attributed to the increasing prevalence of infectious diseases and the rising use of point-of-care immunodiagnostics solutions. However, the inadequate reimbursement scenario is hampering the market growth.
Market Insights
Increasing Prevalence of Infectious Diseases Fuels North America Immunodiagnostics Market Growth
The need for diagnosing & managing infections and other disease is contributing to the rising number of prescriptions for immunodiagnostics tests. There are several immunodiagnostic tests and technologies, such as agglutination tests, complement fixation, precipitation tests, line blot assays, Western blot assays, enzyme immunoassays (EIA), and immunofluorescence tests, developed for infectious diseases.
HIV is a major public health issue worldwide. According to the US Department of Health & Human Services, ~1.2 million people in the US have HIV. The Centers for Disease Control and Prevention (CDC) states that there were ~34,800 new HIV infections in the US in 2019. Similarly, the increasing prevalence of hepatitis, a viral infection that results in liver inflammation, is one of the major factors driving the North America immunodiagnostics market. In 2018, according to the US Department of Health & Human Services (HHS), 2.4 million people live with hepatitis C in the US; the actual upper limit reported is 4.7 million, while the lower limit reported is 2.5 million. Additionally, the WHO's global hepatitis strategy, endorsed by all WHO member states, aims to reduce new hepatitis infections by 90% and deaths by 65% during 2016–2030. The increasing prevalence of infectious diseases fuels North America immunodiagnostics market growth.
The medical industry in North American countries witnessed a chaotic situation, with increased demand for clinical diagnostics and therapeutic systems in hospitals. With the growing infection rate and the rising demand for diagnosis, the immunodiagnostics market experienced a positive impact in the region. Healthcare facilities, clinical laboratories, and pharmaceutical and biotech companies preferred advanced diagnostic techniques and systems to handle the burden of COVID-19.
In March 2021, Eurofins' Clinical Enterprise, Inc. obtained an Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for a direct-to-consumer (DTC) version of its EmpowerDX COVID-19 Home Collection Kit. The Eurofins at-home COVID-19 nasal PCR kit is one of the first over-the-counter SARS-CoV-2 at-home test kits. Similarly, in March 2020, the US FDA issued Emergency Use Authorization (EUA) to Abbott for its fastest available molecular point-of-care test to detect novel coronavirus (COVID-19), which delivers positive results in ~5 minutes and negative results in ~13 minutes. Thus, the rise in product launches during this global health crisis has supported the growth of the North America immunodiagnostics market.
Product-Based Insights
Based on product, the North America immunodiagnostics market is segmented into enzyme-linked immunosorbent assays (ELISA), chemiluminescence immunoassays (CLIA), radioimmunoassays (RIA), and others. The enzyme-linked immunosorbent assays (ELISA) segment held the largest share of the market in 2021. Moreover, the chemiluminescence immunoassays (CLIA) segment is expected to grow at the fastest CAGR during the forecast period.
Clinical Indication -Based Insights
Based on clinical indication, the North America immunodiagnostics market is segmented into infectious diseases, hepatitis+HIV, gastrointestinal endocrinology. The infectious diseases segment held the largest share of the market in 2021, and the same segment is expected to grow at the highest CAGR during the forecast period.
End User-Based Insights
Based on end user, the North America immunodiagnostics market is segmented into hospitals, clinics, diagnostics laboratories, academic & research institutes, and others. The hospitals segment held the largest share of the market in 2021. However, the clinics segment is expected to register the highest CAGR during the forecast period.
Strategic Insights
Product launches and approvals are the commonly adopted strategies by companies to expand their global footprints and product portfolios. Companies in the North America immunodiagnostics market focus on the collaboration strategy to enlarge their clientele, which, in turn, permits them to maintain their brand name across the world.
Immunodiagnostic Market: Competitive Landscape and Key Developments
- In September 2022, Mindray launched the ToRCH Panel. With this panel, the company offers high-quality assays to meet different clinical needs. Mindray ToRCH kits can run tests on various sample types with less quality check controls and sample volumes, which ensures great ease and convenience during clinical detection.
- In August 2022, Roche launched the Elecsys IGRA SARS-CoV-2 test in countries that accept the CE Mark. The Elecsys IGRA SARS-CoV-2 test supports a better understanding of immune response to SARS-CoV-2 infection and vaccination.
- In July 2022, Roche received a Breakthrough Device Designation for the Elecsys ß-Amyloid (1-42) CSF and Elecsys Phospho-Tau (181P) CSF in vitro diagnostic immunoassays, which can measure ß-Amyloid (1-42) and Phospho-Tau concentrations in cerebrospinal fluid (CSF) in adult patients with cognitive impairment, who are being evaluated for Alzheimer’s disease (AD) or other causes of dementia.
A few of the companies included in our research scope are Abbott Laboratories; F. Hoffmann-La Roche Ltd; DiaSorin S.p.A.; Danaher Corp, Thermo Fisher Scientific Inc; Siemens Healthineers AG; PerkinElmer Inc.; Shenzhen Mindray Bio-Medical Electronics Co., Ltd.; and bioMerieux SA
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 North America Immunodiagnostics Market – By Product
1.3.2 North America Immunodiagnostics Market – By Clinical Indication
1.3.3 North America Immunodiagnostics Market – By End User
1.3.4 North America Immunodiagnostics Market– By Country
2. North America Immunodiagnostics Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Immunodiagnostics Market– Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America – PEST Analysis
4.3 Experts Opinion
5. Immunodiagnostics Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Increasing Prevalence of Infectious Diseases
5.1.2 Increasing Use of Point-of-Care Immunodiagnostics
5.2 Market Restraints
5.2.1 Inadequate Reimbursement Scenario
5.3 Market Opportunities
5.3.1 Rising Focus On R&D Investment and Expansion by Key Players
5.4 Future Trends
5.4.1 Technological Advancements in The Field of Immunodiagnostics
5.5 Impact Analysis
6. Immunodiagnostics Market– North America Analysis
6.1 North America Immunodiagnostics Market Revenue Forecast and Analysis
6.1.1 Company Analysis
6.2 Comparative Company Analysis
6.2.1 Market Share Analysis (2021)
6.2.2 Growth Strategy Analysis
6.2.3 Market Positioning of Key Players in Immunodiagnostics Market
6.2.3.1 Abbott
6.2.3.2 F. Hoffmann-La Roche Ltd
7. Immunodiagnostics Market Analysis and Forecasts To 2028 – By Product
7.1 Overview
7.2 North America Immunodiagnostics Market, By Product 2021 & 2028 (%)
7.3 Enzyme-Linked Immunosorbent Assays (ELISA)
7.3.1 Overview
7.3.2 Enzyme-Linked Immunosorbent Assays (ELISA) Market Revenue and Forecast to 2028 (US$ Million)
7.4 Chemiluminescence Immunoassays (CLIA)
7.4.1 Overview
7.4.2 Chemiluminescence Immunoassays (CLIA) Market Revenue and Forecast to 2028 (US$ Million)
7.4.3 Vitamin D Assay
7.4.3.1 Overview
7.4.3.2 Vitamin D Assay Market Revenue and Forecast to 2028 (US$ Million)
7.4.4 HIV Detection
7.4.4.1 Overview
7.4.4.2 HIV Detection Market Revenue and Forecast to 2028 (US$ Million)
7.4.5 HIV Ag/Ab Combo Assay
7.4.5.1 Overview
7.4.5.2 HIV Ag/Ab Combo Assay Market Revenue and Forecast to 2028 (US$ Million)
7.4.6 Others
7.4.6.1 Overview
7.4.6.2 Others Market Revenue and Forecast to 2028 (US$ Million)
7.5 Radioimmunoassays (RIA)
7.5.1 Overview
7.5.2 Radioimmunoassays (RIA) Market Revenue and Forecast to 2028 (US$ Million)
7.6 Others
7.6.1 Overview
7.6.2 Others Market Revenue and Forecast to 2028 (US$ Million)
8. Immunodiagnostics Market Analysis and Forecasts To 2028 – By Clinical Indication
8.1 Overview
8.2 North America Immunodiagnostics Market, By Clinical Indication 2021 & 2028 (%)
8.3 Infectious Diseases
8.3.1 Overview
8.3.2 Infectious Diseases Market Revenue and Forecast to 2028 (US$ Million)
8.3.3 COVID-19
8.3.3.1 Overview
8.3.3.2 COVID-19 Market Revenue and Forecast to 2028 (US$ Million)
8.3.4 Lyme
8.3.4.1 Overview
8.3.4.2 Lyme Market Revenue and Forecast to 2028 (US$ Million)
8.3.5 Zika
8.3.5.1 Overview
8.3.5.2 Zika Market Revenue and Forecast to 2028 (US$ Million)
8.3.6 Infection Management
8.3.6.1 Overview
8.3.6.2 Infection Management Market Revenue and Forecast to 2028 (US$ Million)
8.3.7 TORCH
8.3.7.1 Overview
8.3.7.2 TORCH Market Revenue and Forecast to 2028 (US$ Million)
8.3.8 Tuberculosis
8.3.8.1 Overview
8.3.8.2 Tuberculosis Market Revenue and Forecast to 2028 (US$ Million)
8.3.9 Treponema
8.3.9.1 Overview
8.3.9.2 Treponema Market Revenue and Forecast to 2028 (US$ Million)
8.3.10 Measles and Mumps
8.3.10.1 Overview
8.3.10.2 Measles and Mumps Market Revenue and Forecast to 2028 (US$ Million)
8.3.11 EBV
8.3.11.1 Overview
8.3.11.2 EBV Market Revenue and Forecast to 2028 (US$ Million)
8.3.12 VZV
8.3.12.1 Overview
8.3.12.2 VZV Market Revenue and Forecast to 2028 (US$ Million)
8.4 Hepatitis+HIV
8.4.1 Overview
8.4.2 Hepatitis+HIV Market Revenue and Forecast to 2028 (US$ Million)
8.5 Gastrointestinal
8.5.1 Overview
8.5.2 Gastrointestinal Market Revenue and Forecast to 2028 (US$ Million)
8.6 Metabolics
8.6.1 Overview
8.6.2 Metabolics Market Revenue and Forecast to 2028 (US$ Million)
8.7 Endocrinology
8.7.1 Overview
8.7.2 Endocrinology Market Revenue and Forecast to 2028 (US$ Million)
8.7.3 Hypertension
8.7.3.1 Overview
8.7.3.2 Hypertension Market Revenue and Forecast to 2028 (US$ Million)
8.7.4 GROWTH
8.7.4.1 Overview
8.7.4.2 GROWTH Market Revenue and Forecast to 2028 (US$ Million)
8.7.5 Diabetes
8.7.5.1 Overview
8.7.5.2 Diabetes Market Revenue and Forecast to 2028 (US$ Million)
8.7.6 Thyroid
8.7.6.1 Overview
8.7.6.2 Thyroid Market Revenue and Forecast to 2028 (US$ Million)
8.7.7 Reproductive Endocrinology
8.7.7.1 Overview
8.7.7.2 Reproductive Endocrinology Market Revenue and Forecast to 2028 (US$ Million)
9. Immunodiagnostics Market Analysis and Forecasts To 2028 – By End User
9.1 Overview
9.2 North America Immunodiagnostics Market, By End User 2021 & 2028 (%)
9.3 Hospitals
9.3.1 Overview
9.3.2 Hospitals Market Revenue and Forecast to 2028 (US$ Million)
9.4 Clinics
9.4.1 Overview
9.4.2 Clinics Market Revenue and Forecast to 2028 (US$ Million)
9.5 Diagnostics Laboratories
9.5.1 Overview
9.5.2 Diagnostic Laboratories Market Revenue and Forecast to 2028 (US$ Million)
9.6 Academic and Research Institutes
9.6.1 Overview
9.6.2 Academic and Research Institutes Market Revenue and Forecast to 2028 (US$ Million)
9.7 Others
9.7.1 Overview
9.7.2 Others Market Revenue and Forecast to 2028 (US$ Million)
10. North America Immunodiagnostics Market – Country Analysis
10.1 North America: Immunodiagnostics Market
10.1.1 Overview
10.1.2 North America: Immunodiagnostics Market - Revenue and Forecast to 2028 (USD Million)
10.1.3 North America Immunodiagnostics Market, by Product – Revenue and Forecast to 2028 (USD Million)
10.1.3.1 North America Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2028 (USD Million)
10.1.4 North America Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2028 (USD Million)
10.1.4.1 North America Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2028 (USD Million)
10.1.4.2 North America Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2028 (USD Million)
10.1.5 North America Immunodiagnostics Market, by End User – Revenue and Forecast to 2028 (USD Million)
10.1.6 North America: Immunodiagnostics Market, by Country, 2021 & 2028 (%)
10.1.6.1 US: Immunodiagnostics Market – Revenue and Forecast to 2028 (USD Million)
10.1.6.1.1 US: Immunodiagnostics Market – Revenue and Forecast to 2028 (USD Million)
10.1.6.1.2 US Immunodiagnostics Market, by Product – Revenue and Forecast to 2028 (USD Million)
10.1.6.1.2.1 US Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2028 (USD Million)
10.1.6.1.3 US Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2028 (USD Million)
10.1.6.1.3.1 US Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2028 (USD Million)
10.1.6.1.3.2 US Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2028 (USD Million)
10.1.6.1.4 US: Immunodiagnostics Market, by End User – Revenue and Forecast to 2028 (USD Million)
10.1.6.2 Canada: Immunodiagnostics Market – Revenue and Forecast to 2028 (USD Million)
10.1.6.2.1 Canada: Immunodiagnostics Market – Revenue and Forecast to 2028 (USD Million)
10.1.6.2.2 Canada Immunodiagnostics Market, by Product – Revenue and Forecast to 2028 (USD Million)
10.1.6.2.2.1 Canada Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA) – Revenue and Forecast to 2028 (USD Million)
10.1.6.2.3 Canada Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2028 (USD Million)
10.1.6.2.3.1 Canada Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2028 (USD Million)
10.1.6.2.3.2 Canada Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2028 (USD Million)
10.1.6.2.4 Canada Immunodiagnostics Market, by End User – Revenue and Forecast to 2028 (USD Million)
10.1.6.3 Mexico: Immunodiagnostics Market – Revenue and Forecast to 2028 (USD Million)
10.1.6.3.1 Mexico: Immunodiagnostics Market – Revenue and Forecast to 2028 (USD Million)
10.1.6.3.2 Mexico Immunodiagnostics Market, by Product – Revenue and Forecast to 2028 (USD Million)
10.1.6.3.2.1 Mexico Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA) – Revenue and Forecast to 2028 (USD Million)
10.1.6.3.3 Mexico Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2028 (USD Million)
10.1.6.3.3.1 Mexico Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2028 (USD Million)
10.1.6.3.3.2 Mexico Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2028 (USD Million)
10.1.6.3.4 Mexico Immunodiagnostics Market, by End User – Revenue and Forecast to 2028 (USD Million)
11. North America: Impact Assessment of COVID-19 Pandemic
12. Immunodiagnostics Market –Industry Landscape
12.1 Overview
12.2 Growth Strategies in the Immunodiagnostics Market (%)
12.3 Organic Developments
12.3.1 Overview
12.4 Inorganic Developments
12.4.1 Overview
13. Company Profiles
13.1 Abbott Laboratories
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 F. Hoffmann-La Roche Ltd
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 DiaSorin S.p.A.
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Danaher Corp
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Thermo Fisher Scientific Inc
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Siemens Healthineers AG
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Financial Overview
13.6.4 SWOT Analysis
13.6.5 Key Developments
13.7 PerkinElmer Inc.
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 bioMerieux SA
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
14. Appendix
14.1 About The Insight Partners
14.2 Glossary of Terms
LIST OF TABLES
Table 1. Infectious Diseases and Funding
Table 2. North America Immunodiagnostics Market, by Product – Revenue and Forecast to 2028 (USD Million)
Table 3. North America Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2028 (USD Million)
Table 4. North America Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2028 (USD Million)
Table 5. North America Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2028 (USD Million)
Table 6. North America Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2028 (USD Million)
Table 7. North America Immunodiagnostics Market, by End User- Revenue and Forecast to 2028 (USD Million)
Table 8. US Immunodiagnostics Market, by Product – Revenue and Forecast to 2028 (USD Million)
Table 9. US Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2028 (USD Million)
Table 10. US Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2028 (USD Million)
Table 11. US Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2028 (USD Million)
Table 12. US Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2028 (USD Million)
Table 13. US Immunodiagnostics Market, by End User- Revenue and Forecast to 2028 (USD Million)
Table 14. Canada Immunodiagnostics Market, by Product -Revenue and Forecast to 2028 (USD Million)
Table 15. Canada Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA) -Revenue and Forecast to 2028 (USD Million)
Table 16. Canada Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2028 (USD Million)
Table 17. Canada Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2028 (USD Million)
Table 18. Canada Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2028 (USD Million)
Table 19. Canada Immunodiagnostics Market, by End User – Revenue and Forecast to 2028 (USD Million)
Table 20. Mexico Immunodiagnostics Market, by Product -Revenue and Forecast to 2028 (USD Million)
Table 21. Mexico Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA) -Revenue and Forecast to 2028 (USD Million)
Table 22. Mexico Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2028 (USD Million)
Table 23. Mexico Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2028 (USD Million)
Table 24. Mexico Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2028 (USD Million)
Table 25. Mexico Immunodiagnostics Market, by End User – Revenue and Forecast to 2028 (USD Million)
Table 26. Organic Developments in the Immunodiagnostics Market
Table 27. Inorganic Developments in the Immunodiagnostics Market
Table 28. Glossary of Terms, Immunodiagnostic Market
LIST OF FIGURES
Figure 1. Immunodiagnostics Market Segmentation
Figure 2. Immunodiagnostics Market Segmentation, By Country
Figure 3. North America Immunodiagnostics Market Overview
Figure 4. Enzyme-Linked Immunosorbent Assays (ELISA) Held the Largest Share of the Product Segment in Immunodiagnostics Market
Figure 5. US Held Largest Market Share During Forecast Period
Figure 6. North America Immunodiagnostics Market– Leading Country Markets (US$ Million)
Figure 7. North America Immunodiagnostics Market, Industry Landscape
Figure 8. North America PEST Analysis
Figure 9. Immunodiagnostics Market: Impact Analysis of Drivers and Restraints
Figure 10. North America Immunodiagnostics Market – Revenue Forecast and Analysis – 2020- 2028
Figure 11. Market Share Analysis of Key Players in Immunodiagnostics Market
Figure 12. North America Immunodiagnostics Market – Comparative Company Analysis
Figure 13. North America Immunodiagnostics Market – Growth Strategy Analysis
Figure 14. North America Immunodiagnostics Market, by Product 2021 & 2028 (%)
Figure 15. Enzyme-Linked Immunosorbent Assays (ELISA) Market Revenue and Forecasts to 2028 (US$ Million)
Figure 16. Chemiluminescence Immunoassays (CLIA) Market Revenue and Forecasts To 2028 (US$ Million)
Figure 17. Vitamin D Assay Market Revenue and Forecasts To 2028 (US$ Million)
Figure 18. HIV Detection Market Revenue and Forecasts To 2028 (US$ Million)
Figure 19. HIV Ag/Ab Combo Assay Market Revenue and Forecasts To 2028 (US$ Million)
Figure 20. Others Market Revenue and Forecasts To 2028 (US$ Million)
Figure 21. Radioimmunoassays (RIA) Market Revenue and Forecasts To 2028 (US$ Million)
Figure 22. Others Market Revenue and Forecasts To 2028 (US$ Million)
Figure 23. North America Immunodiagnostics Market, by Clinical Indication 2021 & 2028 (%)
Figure 24. Infectious Diseases Market Revenue and Forecasts to 2028 (US$ Million)
Figure 25. COVID-19 Market Revenue and Forecasts To 2028 (US$ Million)
Figure 26. Lyme Market Revenue and Forecasts To 2028 (US$ Million)
Figure 27. Zika Market Revenue and Forecasts To 2028 (US$ Million)
Figure 28. Infection Management Market Revenue and Forecasts To 2028 (US$ Million)
Figure 29. TORCH Market Revenue and Forecasts To 2028 (US$ Million)
Figure 30. 2.3.5 Tuberculosis Market Revenue and Forecasts To 2028 (US$ Million)
Figure 31. Treponema Market Revenue and Forecasts To 2028 (US$ Million)
Figure 32. Measles and Mumps Market Revenue and Forecasts To 2028 (US$ Million)
Figure 33. EBV Market Revenue and Forecasts To 2028 (US$ Million)
Figure 34. VZV Market Revenue and Forecasts To 2028 (US$ Million)
Figure 35. Hepatitis+HIV Market Revenue and Forecasts to 2028 (US$ Million)
Figure 36. Gastrointestinal Market Revenue and Forecasts to 2028 (US$ Million)
Figure 37. Metabolics Market Revenue and Forecasts to 2028 (US$ Million)
Figure 38. Endocrinology Market Revenue and Forecasts to 2028 (US$ Million)
Figure 39. Hypertension Market Revenue and Forecasts To 2028 (US$ Million)
Figure 40. GROWTH Market Revenue and Forecasts To 2028 (US$ Million)
Figure 41. Diabetes Market Revenue and Forecasts To 2028 (US$ Million)
Figure 42. Throid Market Revenue and Forecasts To 2028 (US$ Million)
Figure 43. Reproductive Endocrinology Market Revenue and Forecasts To 2028 (US$ Million)
Figure 44. North America Immunodiagnostics Market, by End User 2021 & 2028 (%)
Figure 45. Hospitals Market Revenue and Forecasts to 2028 (US$ Million)
Figure 46. Clinics Market Revenue and Forecasts to 2028 (US$ Million)
Figure 47. Diagnostics Laboratories Market Revenue and Forecasts to 2028 (US$ Million)
Figure 48. Research & Academic Institutes Market Revenue and Forecasts to 2028 (US$ Million)
Figure 49. Others Market Revenue and Forecasts to 2028 (US$ Million)
Figure 50. North America: Immunodiagnostics Market, by Key Country – Revenue (2021) (USD Million)
Figure 51. North America Immunodiagnostics Market Revenue and Forecast to 2028 (USD Million)
Figure 52. North America: Immunodiagnostics Market, by Country, 2021 & 2028 (%)
Figure 53. US: Immunodiagnostics Market – Revenue and Forecast to 2028 (USD Million)
Figure 54. Canada: Immunodiagnostics Market – Revenue and Forecast to 2028 (USD Million)
Figure 55. Mexico: Immunodiagnostics Market – Revenue and Forecast to 2028 (USD Million)
Figure 56. Impact of COVID-19 Pandemic on North American Countries Markets
Figure 57. Growth Strategies in the Immunodiagnostics Market (%)
- Abbott Laboratories
- F. Hoffmann-La Roche Ltd
- DiaSorin S.p.A.
- Danaher Corp
- Thermo Fisher Scientific Inc
- Siemens Healthineers AG
- PerkinElmer Inc.
- Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
- bioMerieux SA
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the North America immunodiagnostic market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the immunodiagnostic market in North America, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth regional market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.